Chitosan nanoparticles: A survey of preparation methods

Journal of Drug Targeting

Volumn 20, Issue 4, 2012, Pages 291-300

  Grenha, Ana ^a  

^a UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

Chitosan; desolvation; ionic gelation; nanoparticles; polyelectrolyte complexation; preparation methods

Indexed keywords

BOVINE SERUM ALBUMIN; CARVACROL; CHITOSAN; CHITOSAN NANOPARTICLE; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; EXCIPIENT; FLUOROURACIL; GADOLINIUM; HEPARIN; INSULIN; NANOPARTICLE; OVALBUMIN; POLYPEPTIDE; SAPONIN; TETANUS TOXOID; UNCLASSIFIED DRUG; WATER OIL CREAM;

BIOCOMPATIBILITY; BIOLOGICAL ACTIVITY; COMPLEX FORMATION; CROSS LINKING; DEACETYLATION; DESOLVATION; DIFFUSION; DRUG ABSORPTION; DRUG INDUSTRY; DRUG SAFETY; EMULSION; EMULSION DROPLET COALESCENCE; EMUSLION SOLVENT DIFFUSION; ENCAPSULATION; GELATION; HUMAN; HYDROPHILICITY; IONIC GELATION; LIPOPHILICITY; MICELLIZATION; NEUTRON CAPTURE THERAPY; POLYELECTROLYTE COMPLEXATION; POLYMERIZATION; PRIORITY JOURNAL; RADICAL POLYMERIZATION; REVERSE MICELLIZATION; REVIEW; SHEAR STRENGTH; SOLVATION;

CHITOSAN; DRUG CARRIERS; NANOPARTICLES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84859545586     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.654121     Document Type: Review

References (109)

1. Agnihotri SA, Aminabhavi TM. (2007). Chitosan nanoparticles for prolonged delivery of timolol maleate. Drug Dev Ind Pharm, 33, 1254-1262. (Pubitemid 350208731)
2. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. (2004). Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release, 100, 5-28. (Pubitemid 39445982)
3. Agrawal P, Strijkers GJ, Nicolay K. (2010). Chitosan-based systems for molecular imaging. Adv Drug Deliv Rev, 62, 42-58.
4. Al-Qadi S, Grenha A, Remuñán-López C. (2012). Chitosan and its derivatives as nanocarriers for siRNA delivery. J Drug Deliv Sci Technol (accepted).
5. Al-Qadi S, Grenha A, Carrión-Recio D, Seijo B, Remuñán-López C. (2011). Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J Control Release. doi:10.1016/j.jconrel.2011.08. 008.
6. Alonso MJ. (1996). Nanoparticulate drug carrier technology. In: Cohen S, Bernstein H, eds. Microparticulate Systems for the Delivery of Proteins and Vaccines. New York: Marcel Dekker, 203-242.
7. Alonso MJ. (2004). Nanomedicines for overcoming biological barriers. Biomed Pharmacother, 58, 168-172.
8. Alonso-Sande M, Cuña M, Remuñán-López C, Teijeiro-Osorio D, Alonso-Lebrero JL, Alonso MJ. (2006). Formation of new glucomannan-chitosan nanoparticles and study of their ability to associate and deliver proteins. Macromolecules, 39, 4152-4158. (Pubitemid 44021312)
9. Andrade F, Antunes F, Nascimento AV, da Silva SB, das Neves J, Ferreira D, Sarmento B. (2011). Chitosan formulations as carriers for therapeutic proteins. Curr Drug Discov Technol, 8, 157-172.
10. Anto SM, Kannan C, Kumar KS, Kumar SV, Suganeshwari M. (2011). Formulation of 5-fluorouracil loaded chitosan nanoparticles by emulsion droplet coalescence method for cancer therapy. Int J Pharm Biol Arch, 2, 926-931.
11. Atyabi F, Talaie F, Dinarvand R. (2009). Thiolated chitosan nanoparticles as an oral delivery system for Amikacin: in vitro and ex vivo evaluations. J Nanosci Nanotechnol, 9, 4593-4603.
12. Avadi MR, Sadeghi AM, Mohammadpour N, Abedin S, Atyabi F, Dinarvand R, Rafiee-Tehrani M. (2010). Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomedicine, 6, 58-63.
13. Azizi E, Namazi A, Haririan I, Fouladdel S, Khoshayand MR, Shotorbani PY, Nomani A, Gazori T. (2010). Release profile and stability evaluation of optimized chitosan/alginate nanoparticles as EGFR antisense vector. Int J Nanomedicine, 5, 455-461.
14. Baldrick P. (2010). The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol, 56, 290-299.
15. Banerjee T, Mitra S, Kumar Singh A, Kumar Sharma R, Maitra A. (2002). Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm, 243, 93-105.
16. Bayat A, Larijani B, Ahmadian S, Junginger HE, Rafiee-Tehrani M. (2008). Preparation and characterization of insulin nanoparticles using chitosan and its quaternized derivatives. Nanomedicine, 4, 115-120.
17. Berthold A, Cremer K, Kreuter J. (1996). Preparation and characterisation of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs. J Control Rel, 39, 17-25. (Pubitemid 26139808)
18. Bhattarai N, Gunn J, Zhang M. (2010). Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev, 62, 83-99.
19. Bisht S, Maitra A. (2009). Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 1, 415-425.
20. Blau S, Jubeh TT, Haupt SM, Rubinstein A. (2000). Drug targeting by surface cationization. Crit Rev Ther Drug Carrier Syst, 17, 425-465.
21. Bodmeier R, Chen HG, Paeratakul O. (1989). A novel approach to the oral delivery of micro- or nanoparticles. Pharm Res, 6, 413-417. (Pubitemid 19176086)
22. Bonferoni MC, Sandri G, Rossi S, Ferrari F, Caramella C. (2009). Chitosan and its salts for mucosal and transmucosal delivery. Expert Opin Drug Deliv, 6, 923-939.
23. Borges O, Borchard G, Verhoef JC, de Sousa A, Junginger HE. (2005). Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm, 299, 155-166. (Pubitemid 40962417)
24. Bowman K, Leong KW. (2006). Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine, 1, 117-128.
25. Calvo P, Remuñan-Lopez C, Vila-Jato JL, Alonso MJ. (1997). Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci, 63, 125-132. (Pubitemid 127613982)
26. Canelas DA, Herlihy KP, DeSimone JM. (2009). Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 1, 391-404.
27. Carvalho EL, Grenha A, Remuñán-López C, Alonso MJ, Seijo B. (2009). Mucosal delivery of liposome-chitosan nanoparticle complexes. Meth Enzymol, 465, 289-312.
28. Chan HK, Kwok PC. (2011). Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev, 63, 406-416.
29. Chaudhury A, Das S. (2011). Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents. AAPS PharmSciTech, 12, 10-20.
30. Chiellini F, Piras AM, Errico C, Chiellini E. (2008). Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine (Lond), 3, 367-393. (Pubitemid 351827313)
31. Csaba N, Garcia-Fuentes M, Alonso MJ. (2006). The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Deliv, 3, 463-478.
32. Cuña M, Alonso-Sandel M, Remuñán-López C, Pivel JP, Alonso-Lebrero JL, Alonso MJ. (2006). Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. J Nanosci Nanotechnol, 6, 2887-2895. (Pubitemid 44579959)
33. das Neves J, Bahia MF, Amiji MM, Sarmento B. (2011). Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Expert Opin Drug Deliv, 8, 1085-1104.
34. De Campos AM, Sánchez A, Alonso MJ. (2001). Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm, 224, 159-168. (Pubitemid 32706495)
35. de la Fuente M, Csaba N, Garcia-Fuentes M, Alonso MJ. (2008a). Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine, 3, 845-857.
36. de la Fuente M, Seijo B, Alonso MJ. (2008b). Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophtalmol Vis Sci, 49, 2016-2024.
37. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. (1996). Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res, 13, 1838-1845. (Pubitemid 27034116)
38. Du J, Sun R, Zhang S, Govender T, Zhang LF, Xiong CD, Peng YX. (2004). Novel polyelectrolyte carboxymethyl konjac glucomannanchitosan nanoparticles for drug delivery. Macromol Rapid Commun, 25, 954-958.
39. Duceppe N, Tabrizian M. (2010). Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin Drug Deliv, 7, 1191-1207.
40. El-Shabouri MH. (2002). Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm, 249, 101-108.
41. Elsayed A, Al-Remawi M, Qinna N, Farouk A, Al-Sou'od KA, Badwan AA. (2011). Chitosan-sodium lauryl sulfate nanoparticles as a carrier system for the in vivo delivery of oral insulin. AAPS PharmSciTech, 12, 958-964.
42. Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. (1998). Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res, 15, 1332-1339. (Pubitemid 28427918)
43. Fan W, Yan W, Xu Z, Ni H. (2012). Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces, 90, 21-27.
44. FDA. (2005). Guidance for industry - Nonclinical studies for the safety evaluation of pharmaceutical excipients. [Online] Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm079250.pdf. Accessed 8 December 2011.
45. Goycoolea FM, Lollo G, Remuñán-López C, Quaglia F, Alonso MJ. (2009). Chitosan-alginate blended nanoparticles as carriers for the transmucosal delivery of macromolecules. Biomacromolecules, 10, 1736-1743.
46. Grabnar PA, Kristl J. (2010). Physicochemical characterization of protein-loaded pectin-chitosan nanoparticles prepared by polyelectrolyte complexation. Pharmazie, 65, 851-852.
47. Grenha A, Al-Qadi S, Seijo B, Remuñán-Lopez C. (2010a). The potential of chitosan for pulmonary drug delivery. J Drug Deliv Sci Technol, 20, 33-43.
48. Grenha A, Gomes ME, Rodrigues M, Santo VE, Mano JF, Neves NM, Reis RL. (2010b). Development of new chitosan/carrageenan nanoparticles for drug delivery applications. J Biomed Mater Res A, 92, 1265-1272.
49. Grenha A, Seijo B, Remuñán-López C. (2005). Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci, 25, 427-437. (Pubitemid 40853870)
50. Hirano S, Seino H, Akiyama Y, Nonaka I. (1988). Biocompatibility of chitosan by oral and intravenous administrations. Polym Mater Sci Eng, 59, 897-901.
51. Hu Y, Jiang X, Ding Y, Ge H, Yuan Y, Yang C. (2002). Synthesis and characterization of chitosan-poly(acrylic acid) nanoparticles. Biomaterials, 23, 3193-3201. (Pubitemid 34525103)
52. Huang M, Khor E, Lim LY. (2004). Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res, 21, 344-353. (Pubitemid 38221982)
53. Ichikawa H, Tokumitsu H, Miyamoto M, Fukumori Y. (2006). Nanoparticles for neutron capture therapy of cancer. In: Kumar C, ed. Nanomaterials for Cancer Therapy. Weinheim: Wiley-VCH, 87-121.
54. Janes KA, Calvo P, Alonso MJ. (2001). Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev, 47, 83-97. (Pubitemid 32209234)
55. Jani P, Halbert GW, Langridge J, Florence AT. (1990). Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol, 42, 821-826.
56. Kaihara S, Suzuki Y, Fujimoto K. (2011). In situ synthesis of polysaccharide nanoparticles via polyion complex of carboxymethyl cellulose and chitosan. Colloids Surf B Biointerfaces, 85, 343-348.
57. Kean T, Thanou M. (2010). Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev, 62, 3-11.
58. Keawchaoon L, Yoksan R. (2011). Preparation, characterization and in vitro release study of carvacrol-loaded chitosan nanoparticles. Colloids Surf B Biointerfaces, 84, 163-171.
59. Kissel T, Maretscheck S, Packhäuser C, Schnieders J, Seidel N. (2006). Microencapsulation techniques for parenteral depot systems and their application in the pharmaceutical industry. In: Benita S, ed. Microencapsulation: Methods and Industrial Applications. New York: Taylor & Francis, 99-122.
60. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. (1992). In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm, 78, 43-48.
61. Lin YH, Mi FL, Chen CT, Chang WC, Peng SF, Liang HF, Sung HW. (2007). Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules, 8, 146-152.
62. Lin YH, Sonaje K, Lin KM, Juang JH, Mi FL, Yang HW, Sung HW. (2008). Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J Control Release, 132, 141-149.
63. Liu H, Chen B, Mao Z, Gao C. (2007a). Chitosan nanoparticles for loading of toothpaste actives and adhesion on tooth analogs. J Appl Polym Sci, 106, 4248-4256. (Pubitemid 350149397)
64. Liu Z, Jiao Y, Liu F, Zhang Z. (2007b). Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation. J Biomed Mater Res A, 83, 806-812. (Pubitemid 350086307)
65. Luppi B, Bigucci F, Cerchiara T, Zecchi V. (2010). Chitosan-based hydrogels for nasal drug delivery: from inserts to nanoparticles. Expert Opin Drug Deliv, 7, 811-828.
66. Ma Z, Yeoh HH, Lim LY. (2002). Formulation pH modulates the interaction of insulin with chitosan nanoparticles. J Pharm Sci, 91, 1396-1404. (Pubitemid 34633955)
67. Malam Y, Lim EJ, Seifalian AM. (2011). Current trends in the application of nanoparticles in drug delivery. Curr Med Chem, 18, 1067-1078.
68. Manchanda R, Nimesh R. (2010). Controlled size chitosan nanoparticles as an efficient, biocompatible oligonucleotides delivery system. J Appl Polym Sci, 118, 2071-2077.
69. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW. (2001). Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release, 70, 399-421. (Pubitemid 32155463)
70. Maurya SK, Pathak K, Bali V. (2010). Therapeutic potential of mucoadhesive drug delivery systems-an updated patent review. Recent Pat Drug Deliv Formul, 4, 256-265.
71. Mitra S, Gaur U, Ghosh PC, Maitra AN. (2001). Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release, 74, 317-323. (Pubitemid 32727639)
72. Nagpal K, Singh SK, Mishra DN. (2010). Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull, 58, 1423-1430.
73. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. (1993). Preparation of biodegradable nanospheres of water soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Rel, 2, 89-98. (Pubitemid 23168633)
74. Ohya Y, Shiratani M, Kobayashi H, Ouchi T. (1994). Release behaviour of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and their cell specific cytotoxicity. Pure Appl Chem, A31, 629-642.
75. Oyarzun-Ampuero FA, Brea J, Loza MI, Torres D, Alonso MJ. (2009). Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int J Pharm, 381, 122-129.
76. Park JH, Saravanakumar G, Kim K, Kwon IC. (2010). Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev, 62, 28-41.
77. Pileni MP. (2006). Reverse micelles used as templates: a new understanding in nanocrystal growth. J Experim Nanosci, 1, 13-27.
78. Poncelet D. (2005). Microencapsulation: fundamentals, methods and applications. In: Blitz JP, Gun'ko VM, eds. Surface Chemistry in Biomedical and Environmental Science. Dordrecht: Springer, 23-34.
79. Posadas I, Guerra FJ, Ceña V. (2010). Nonviral vectors for the delivery of small interfering RNAs to the CNS. Nanomedicine (Lond), 5, 1219-1236.
80. Prabaharan M, Mano JF. (2005). Chitosan-based particles as controlled drug delivery systems. Drug Deliv, 12, 41-57. (Pubitemid 40066260)
81. Rejinold N, Muthunarayanan M, Muthuchelian K, Chennazhi K, Nair S, Jayakumar R. (2011). Saponin-loaded chitosan nanoparticles and their cytotoxicity to cancer cell lines in vitro. Carb Polym, 84, 407-416.
82. Sajeesh S, Sharma CP. (2006a). Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm, 325, 147-154. (Pubitemid 44573692)
83. Sajeesh S, Sharma CP. (2006b). Novel pH responsive polymethacrylic acid-chitosan-polyethylene glycol nanoparticles for oral peptide delivery. J Biomed Mater Res Part B Appl Biomater, 76, 298-305. (Pubitemid 43165387)
84. Sarmento B, Martins S, Ribeiro A, Veiga F, Neufeld R, Ferreira D. (2006a). Development and comparison of different nanoparticulate polyelectrolyte complexes as insulin carriers. Int J Peptide Res Ther, 12, 131-138. (Pubitemid 43881841)
85. Sarmento B, Ribeiro A, Veiga F, Ferreira D. (2006b). Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids Surf B Biointerfaces, 53, 193-202. (Pubitemid 44802985)
86. Sarmento, Ribeiro A, Veiga F, Ferreira D, Neufeld R. (2007). Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules, 8, 3054-3060.
87. Schipper NG, Vårum KM, Artursson P. (1996). Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res, 13, 1686-1692. (Pubitemid 26426893)
88. Schipper NG, Vârum KM, Stenberg P, Ocklind G, Lennernäs H, Artursson P. (1999). Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. Eur J Pharm Sci, 8, 335-343. (Pubitemid 29325026)
89. Silva GA, Coutinho OP, Ducheyne P, Shapiro IM, Reis RL. (2007). Starch-based microparticles as vehicles for the delivery of active platelet-derived growth factor. Tissue Eng, 13, 1259-1268. (Pubitemid 46986726)
90. Songjiang Z, Lixiang W. (2009). Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech, 10, 900-905.
91. Takeuchi H, Yamamoto H, Kawashima Y. (2001). Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev, 47, 39-54. (Pubitemid 32209231)
92. Tan ML, Choong PF, Dass CR. (2009). Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol, 61, 3-12.
93. Tang ZX, Qian JQ, Shi LE. (2007). Preparation of chitosan nanoparticles as carrier for immobilized enzyme. Appl Biochem Biotechnol, 136, 77-96.
94. Teijeiro-Osorio D, Remuñán-López C, Alonso MJ. (2009). New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules, 10, 243-249.
95. Terbojevich M, Muzzarelli RAA. (2009). Chitosan. In: Phillips GO, Williams P, eds. Handbook of Hydrocolloids. Cambridge: Woodhead Publishing Ltd., 367-378.
96. Tian XX, Groves MJ. (1999). Formulation and biological activity of antineoplastic proteoglycans derived from Mycobacterium vaccae in chitosan nanoparticles. J Pharm Pharmacol, 51, 151-157.
97. Tiera MJ, Shi Q, Winnik FM, Fernandes JC. (2011). Polycation-based gene therapy: current knowledge and new perspectives. Curr Gene Ther, 11, 288-306.
98. Tiyaboonchai W. (2003). Chitosan nanoparticles: a promising system for drug delivery. Naresuan Univ J, 11, 51-66.
99. Tokumitsu H, Ichikawa H, Fukumori Y, Block LH. (1999a). Preparation of gadopentetic acid-loaded chitosan microparticles for gadolinium neutron-capture therapy of cancer by a novel emulsion-droplet coalescence technique. Chem Pharm Bull, 47, 838-842. (Pubitemid 29315373)
100. Tokumitsu H, Ichikawa H, Fukumori Y. (1999b). Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: preparation by novel emulsion-droplet coalescence technique and characterization. Pharm Res, 16, 1830-1835. (Pubitemid 30040698)
101. Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, Wang SL. (2011a). Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine, 6, 765-774.
102. Wang J, Byrne JD, Napier ME, DeSimone JM. (2011b). More effective nanomedicines through particle design. Small, 7, 1919-1931.
103. Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm, 70, 735-740.
104. Xu J, Dai W, Wang Z, Chen B, Li Z, Fan X. (2011). Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin Vaccine Immunol, 18, 75-81.
105. Xu Y, Du Y. (2003). Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm, 250, 215-226.
106. Yang SJ, Lin FH, Tsai HM, Lin CF, Chin HC, Wong JM, Shieh MJ. (2011). Alginate-folic acid-modified chitosan nanoparticles for photodynamic detection of intestinal neoplasms. Biomaterials, 32, 2174-2182.
107. Yeh MK, Cheng KM, Hu CS, Huang YC, Young JJ. (2011). Novel protein-loaded chondroitin sulfate-chitosan nanoparticles: preparation and characterization. Acta Biomater, 7, 3804-3812.
108. Zhang H, Oh M, Allen C, Kumacheva E. (2004). Monodisperse chitosan nanoparticles for mucosal drug delivery. Biomacromolecules, 5, 2461-2468. (Pubitemid 39585302)
109. Zheng C, Yan W, Li-Jun Z, Zhong-Qiu L. (2010). Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab, 11, 197-207.